-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-579 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBVCLS-579 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBVCLS-579 in Solid Tumor Drug Details: ABBVCLS-579 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-579 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBVCLS-579 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBVCLS-579 in Renal Cell Carcinoma Drug Details: ABBVCLS-579 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-579 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBVCLS-579 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBVCLS-579 in Non-Small Cell Lung Cancer Drug Details: ABBVCLS-579...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-579 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBVCLS-579 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBVCLS-579 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Pancreatic Cancer Drug Details: Diakine-DK210 (EGFR) is under...
-
Product Insights
Memory Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Memory Impairment - Drugs In Development, 2023’, provides an overview of the Memory Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Memory Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Marginal Zone B-cell Lymphoma Drug Details: ZNd-5...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBVCLS-7262 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBVCLS-7262 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBVCLS-7262 in Amyotrophic Lateral Sclerosis Drug Details: ABBVCLS-7262 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-474121 in Cognitive Impairment Associated With Schizophrenia (CIAS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BI-474121 in Cognitive Impairment Associated With Schizophrenia (CIAS)Drug Details:BI-474121 is under development for the treatment of...